Publications

Halabi S, Guo S, Luo B, Yu C, Knutson TP, Kobilka A, Lyman J, Beltran H, Antonarakis ES, Galsky MD, Rosenberg JE, Ryan CJ, Small EJ, Kelly WK, Morris MJ, Page D, Dehm SM, Armstrong AJ. Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer. European urology. 2025. PMID: 40774853


Leeman JE, Shin KY, Droznin A, Catalano P, Cagney DN, Singer L, Oniyangi RD, Zhai K, Benham G, Chirmade S, Campbell J, Boyle S, Saranteas A, Williams CL, Huynh E, Han Z, Sudhyadhom A, Hu YH, Ferguson D, Singhrao K, Hsu SH, Bredfeldt J, Martin NE, Mancias JD, Mamon HJ, Van Dams R, Venkatachalam V, Tanguturi SK, Huynh MA, Fitzgerald KJ, Elhalawani H, Bitterman DS, Schoenfeld JD, Nguyen P, Haas-Kogan DA, Mak R. Stereotactic MRI Guided Adaptive Radiotherapy: a pooled analysis of a master prospective trial. Journal of the National Cancer Institute. 2025. PMID: 40794880


Battaglin F, O'Neil BH, Stintzing S, Ou FS, Zemla TJ, Niedzwiecki D, Innocenti F, Hochster HS, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Heintges T, Lerchenmüller C, Weiss L, Heinrich K, Goldberg RM, Mayer RJ, Schilsky RL, Blanke CD, Venook AP, Lenz HJ, Heinemann V. Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance). European journal of cancer (Oxford, England : 1990). 2025. PMID: 40803104


Williams BM, Mulima G, Kaimila B, Marapese KD, Salima AW, Evans A, Ngwira N, Kajombo C, Gallaher J, Charles A, McGinty K, Buckle G, Mody GN. Esophageal Cancer Staging in Malawi: The Feasibility of Chest Radiography and Abdominal Ultrasound for Initial Evaluation. Research square. 2025. PMID: 40799736


Rugo HS, Tokunaga E, Iwata H, Petry V, Smit EF, Goto Y, Kim DW, Shitara K, Gruden JF, Modi S, Cortés J, Krop I, Jänne PA, Cheng Y, Taitt C, Cheng FC, Powell CA. Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis. Annals of oncology : official journal of the European Society for Medical Oncology. 2025. PMID: 40769277


Tolani MA, Agbo CA, Umar SS, Paciorek A, Ojewola RW, Mohammed F, Maiga M, Kaninjing E, Ahmed M, DeBoer R. An intervention mapping approach to the development and evaluation of a community-based prostate cancer early detection programme in Nigeria. PLOS global public health. 2025. PMID: 40763189


Rugo H, Bardia A, Bruno DS, Ernani V, Hamilton E, Heist R, Jhaveri K, Levy B, Lisberg A, O'Shaughnessy J, Sands J, Spira A, Tolaney S, Treister NS, Matthews C, Johnson M. US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2025. PMID: 40762824


Miao X, Su P, Ohliger MA, Yang Y, Pang J, Hotca AE, Hope TA, Hong CW, Bergsland EK, Feng M, Scholey JE. 4D-MRI at 0.55T for internal target volume delineation in liver radiation therapy planning. Medical physics. 2025. PMID: 40903915


Roy S, Ozay ZI, Guha A, Sun Y, Chi KN, Morgan SC, Malone S, Wallis CJD, Brown JR, Barata PC, Kishan AU, Jia AY, Zaorsky NG, Swami U, Chowdhury S, Small EJ, Spratt DE, Saad F, Agarwal N. Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials. JAMA network open. 2025. PMID: 40833694


Caston NE, Deng L, Williams CP, Levitan EB, Azuero A, Griffin R, Smith KL, Wolff AC, Melisko ME, Shinn EH, Gallagher K, Angove R, Wheeler SB, Rocque GB. Understanding Associations Between Patient-Level Factors and Participation in a Breast Cancer Clinical Trial. Cancer medicine. 2025. PMID: 40836443


Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees MJ, Costello P, Vazquez Martinez MA, Pasvolsky O, Wagner CB, Davis JA, Castaneda Puglianini OA, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo RD, Freeman CL, Mikkilineni L, Raza S, Anderson LD, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa MR, Midha S, Alsina M, Sborov DW, Patel KK, Lin Y, Ferreri CJ, Gagelmann N, Kumar AD, Hansen DK, Cowan AJ, Costa LJ, Merz M, Sidana S. Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy. Blood. 2025. PMID: 40749169


Iagaru A, Suarez JF, Behr S, Aggarwal R, Paredes P, Buffi N, Penhoat T, Ceci F, Walz J, Doumerc N, Coulanges M, Xu Z, Seigne C, Wilke C, Catafau AM, Fanti S, Maurer T, GuideView study investigators. Imaging Efficacy of [18F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2025. PMID: 40473463


Le C, Lewis M, Harris CS, Berger L, Chavez-Iglesias E, Morse L, Sucher A, Roy R, Olshen A, Hammer MJ, Paul S, Wallhagen M, Chan R, Sayer M, Yom S, Cho NW, Chan A, Levine J, Dhruva A, Miaskowski C, Conley YP, Kober KM. A Data-Driven Epigenetic Characterization of Morning Fatigue Severity in Oncology Patients Receiving Chemotherapy: Associations With Epigenetic Age Acceleration, Blood Cell Types, and Expression-Associated Methylation. Cancer medicine. 2025. PMID: 40709591


Fanti S, Robles Barba JJ, Behr S, Maurer T, Paredes P, Walz J, Duch J, Perdigo MS, Mainta IC, Bonnefoy PB, Coulanges M, Tang J, Seigne C, Wilke C, Catafau AM, Iagaru A, Aggarwal R. Imaging Efficacy of [18F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2025. PMID: 40473464


Milhem MM, Zakharia Y, Davar D, Buchbinder EI, Medina T, Daud A, Ribas A, Chmielowski B, Niu J, Gibney GT, Margolin K, Olszanski AJ, Mehmi I, Sato T, Shaheen M, Zhao L, Kelley H, Liu H, Kumar S, Bobilev D, Krieg AM, Wooldridge JE, Kirkwood JM. Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study. Cancer. 2025. PMID: 40753466


Beresis R, Prathigudupu V, Cable C, Yu A, Adler M, Ramamoorthi R, Yeon SK, Gordan JD, Sharma S, DeGrado WF, Zaro B, Chen JY, Jo H. Exploration of a Class of Aryl Imidazolyl Ureas As Potent Acid Ceramidase Inhibitors for the Treatment of Fibrotic Diseases. ACS omega. 2025. PMID: 40821548


Chen HY, de Kouchkovsky I, Bok RA, Ohliger MA, Wang ZJ, Gebrezgiabhier D, Nickles T, Carvajal L, Gordon JW, Larson PEZ, Kurhanewicz J, Aggarwal R, Vigneron DB. Correction: Chen et al. Multivariate Framework of Metabolism in Advanced Prostate Cancer Using Whole Abdominal and Pelvic Hyperpolarized 13C MRI-A Correlative Study with Clinical Outcomes. Cancers 2025, 17, 2211. Cancers. 2025. PMID: 40805300


Hawes MR, Chakravarty D, Cheng J, Handley MA, Tsoh JY, Lin TK, Hiatt RA, Vijayaraghavan M. The Healthy Homes Study: Protocol for a cluster randomized trial of a place-based smoke-free home intervention in affordable housing. PloS one. 2025. PMID: 40729126


Chan SL, Sun HC, Xu Y, Zeng H, El-Serag HB, Lee JM, Schwartz ME, Finn RS, Seong J, Wang XW, Paradis V, Abou-Alfa GK, Rimassa L, Kao JH, Zhang BH, Llovet JM, Bruix J, Yip TC, Wong VW, Wong GL, Chan LL, Liu MQ, Gao Q, Shen F, Kelley RK, Cheng AL, Kurosaki M, Toyoda H, Chen WX, Murakami T, Liang P, Zucman-Rossi J, Minami Y, Miyayama S, Wang K, Man K, Hasegawa K, Li Q, Tsuchiya K, Xu L, Chew V, Chow P, Hoshida Y, Lujambio A, Ng IO, Sakamoto M, Park YN, Yau T, Kudo M, Fan J, Zhou J. The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment. Lancet (London, England). 2025. PMID: 40744051